Christine L. Phillips, MD
- Medical Director, Division of Oncology
- Director, CAR T and Immunotherapy
- Associate Professor, UC Department of Pediatrics
- christine.phillips@cchmc.org
- Board Certified
About
Biography
Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.
Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.
MD: Indiana University School of Medicine, Indianapolis, IN, 2002.
Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.
Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.
Services and Specialties
Cancer and Blood Diseases, Leukemia, Fertility Preservation
Research Areas
Oncology
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205:1055-1066.
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns. EClinicalMedicine. 2023; 65:102268.
Mediport use as an acceptable standard for CAR T cell infusion. Frontiers in Immunology. 2023; 14:1239132.
Male pediatric, adolescent, and young adult reproductive survivorship. Pediatric Blood and Cancer. 2023; 70 Suppl 5:e28823.
Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.
Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer. 2023; 70:e30271.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Advances. 2023; 7:541-548.
Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.
Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2023; 29:130.e1-130.e8.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey